CN114761003B - 具有雄激素受体降解活性的新型脲类及其用途 - Google Patents

具有雄激素受体降解活性的新型脲类及其用途 Download PDF

Info

Publication number
CN114761003B
CN114761003B CN202080079154.8A CN202080079154A CN114761003B CN 114761003 B CN114761003 B CN 114761003B CN 202080079154 A CN202080079154 A CN 202080079154A CN 114761003 B CN114761003 B CN 114761003B
Authority
CN
China
Prior art keywords
piperidin
carboxamide
piperazin
methyl
dimethylpiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202080079154.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114761003A (zh
Inventor
范捷
Y.钱
W.何
刘坷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accutar Biotechnology Inc
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Publication of CN114761003A publication Critical patent/CN114761003A/zh
Application granted granted Critical
Publication of CN114761003B publication Critical patent/CN114761003B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080079154.8A 2019-09-23 2020-09-22 具有雄激素受体降解活性的新型脲类及其用途 Expired - Fee Related CN114761003B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903997P 2019-09-23 2019-09-23
US62/903,997 2019-09-23
PCT/US2020/051997 WO2021061642A1 (en) 2019-09-23 2020-09-22 Novel ureas having androgen receptor degradation activity and uses thereof

Publications (2)

Publication Number Publication Date
CN114761003A CN114761003A (zh) 2022-07-15
CN114761003B true CN114761003B (zh) 2023-12-29

Family

ID=74879893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079154.8A Expired - Fee Related CN114761003B (zh) 2019-09-23 2020-09-22 具有雄激素受体降解活性的新型脲类及其用途

Country Status (5)

Country Link
US (3) US11420956B2 (https=)
EP (1) EP4034114A4 (https=)
JP (1) JP2022549222A (https=)
CN (1) CN114761003B (https=)
WO (1) WO2021061642A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
EP3917916A4 (en) 2019-01-30 2022-12-14 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
AU2021311245A1 (en) * 2020-07-21 2023-03-09 Ubix Therapeutics, Inc. Compound for androgen receptor degradation, and pharmaceutical use thereof
WO2023039604A1 (en) * 2021-09-13 2023-03-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
KR20230112501A (ko) 2022-01-20 2023-07-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해활성을 갖는 화합물 및 이들의 의약 용도
US20240190842A1 (en) * 2022-11-09 2024-06-13 Accutar Biotechnology Inc. Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003502A1 (en) * 1996-07-24 1998-01-29 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
EP3135669A1 (en) * 2014-04-24 2017-03-01 Dong-A ST Co., Ltd. Oxazolidine-based compound and selective androgen receptor agonist comprising same
CN108048567A (zh) * 2012-07-27 2018-05-18 阿拉贡药品公司 用于确定抵抗雄激素受体疗法的方法和组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1129581C (zh) * 1998-09-22 2003-12-03 山之内制药株式会社 氰基苯基衍生物
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
AU2003248052A1 (en) * 2002-07-12 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. N-phenyl-(2r,5s)dimethylpiperadine derivative
WO2005011011A1 (en) * 2003-07-21 2005-02-03 Unaxis Usa Inc. Etching method for making chalcogenide memory elements
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
EA201390598A1 (ru) * 2010-10-22 2013-08-30 Астеллас Фарма Инк. Антагонист мутантного андрогенного рецептора
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003502A1 (en) * 1996-07-24 1998-01-29 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
CN108048567A (zh) * 2012-07-27 2018-05-18 阿拉贡药品公司 用于确定抵抗雄激素受体疗法的方法和组合物
EP3135669A1 (en) * 2014-04-24 2017-03-01 Dong-A ST Co., Ltd. Oxazolidine-based compound and selective androgen receptor agonist comprising same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
雄激素非依赖性前列腺癌细胞雄激素受体靶向降解的实验研究;施云峰等;《中华男科学杂志》;20091220;第15卷(第12期);第1059-1063页 *

Also Published As

Publication number Publication date
JP2022549222A (ja) 2022-11-24
US20210300901A1 (en) 2021-09-30
US11420956B2 (en) 2022-08-23
WO2021061642A1 (en) 2021-04-01
EP4034114A4 (en) 2023-07-26
US20230150973A1 (en) 2023-05-18
US11220490B2 (en) 2022-01-11
CN114761003A (zh) 2022-07-15
EP4034114A1 (en) 2022-08-03
US20210087170A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CN114761003B (zh) 具有雄激素受体降解活性的新型脲类及其用途
JP7307796B2 (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
CN113164409B (zh) 具有雌激素受体α降解活性的化合物及其用途
EP4420728A2 (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
WO2021061644A1 (en) Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
US12234218B2 (en) Heterocyclic compounds as modulators of mGluR7
EP3569592B1 (en) Hdac6 selective inhibitors, preparation method therefor, and application thereof
JP2024527577A (ja) ３，４－メチレンジオキシメタンフェタミン及び関連する幻覚剤ならびにその使用
KR102547709B1 (ko) 아제티딘 유도체
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
WO2024102784A1 (en) Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof
HK40041475B (en) Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
HK40041475A (en) Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
HK40115205A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
KR20260054707A (ko) Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 응용
IL319492A (en) A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20231229

CF01 Termination of patent right due to non-payment of annual fee